Fig. 3From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVEOverall NEDA over 2 years stratified by baseline characteristics. Patients who did not achieve NEDA at year 1 and who had missing data at year 2 were included in the analysis population. Statistically significant outcomes are shown in bold. CI = confidence interval; EDSS = Expanded Disability Status Scale; Gd + = gadolinium enhancing; MS = multiple sclerosis; NEDA = no evidence of disease activity; OR = odds ratioBack to article page